Heart failure with preserved ejection fraction: Pathophysiology and emerging therapies

Aaron M. From, Barry A. Borlaug

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Approximately half of patients with heart failure (HF) have a preserved ejection fraction (HFpEF). Morbidity and mortality are similar to HF with reduced EF (HFrEF), yet therapies with unequivocal benefit in HFrEF have not been shown to be effective in HFpEF. Recent studies have shown that the pathophysiology of HFpEF, initially believed to be due principally to diastolic dysfunction, is more complex. Appreciation of this complexity has shed new light into how HFpEF patients might respond to traditional HF treatments, while also suggesting new applications for novel therapies and strategies. In this review, we shall briefly review the pathophysiologic mechanisms in HFpEF, currently available clinical trial data, and finally explore new investigational therapies that are being developed and tested in ongoing and forthcoming trials.

Original languageEnglish (US)
JournalCardiovascular Therapeutics
Issue number4
StatePublished - Aug 1 2011


  • Diastole
  • Heart failure
  • Heart failure with preserved ejection fraction
  • Hypertension
  • Pathophysiology
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Heart failure with preserved ejection fraction: Pathophysiology and emerging therapies'. Together they form a unique fingerprint.

Cite this